Drug intelligence / Profile preview

eciruciclib

Development stage: Phase 2
Lead developer: Beta Pharma
Modality: Small Molecules
Administration: Oral

Overview

Eciruciclib (BPI-1178) is an orally bioavailable small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Developed by Beta Pharma, it is designed to arrest the cell cycle in the G1 phase, thereby inhibiting the proliferation of cancer cells. It is currently being investigated in Phase 1/2a clinical trials for the treatment of advanced solid tumors and hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, both as a monotherapy and in combination with endocrine therapies such as fulvestrant or letrozole.

Other names: eciruciclib

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on eciruciclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eciruciclib.

Explore the full profile